SARS-CoV-2 InfectionNCT04636203
Burden of COVID-19 Infection in Populations With High or Low Risk of Infection
An observational study of SARS-CoV-2 Infection and Covid19, run by Neuromed IRCCS at 2 sites in Italy.
Trial summary
Introduction. Some issues remain to be elucidated about SARS-CoV-2 infection to plan prevention interventions based on scientific evidence, such as the actual prevalence of infection including subclinical and seroconverted cases, the reasons for the different spread and severity of the infection in different subjects… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- SARS-CoV-2 Infection, Covid19
- How many people
- 4,000 participants
- Where
- 2 sitesItaly
- Study dates
- 15 Jan 2020to 31 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: General population Residents in the territories of ASST Sette Laghi (Lombardia) and of Molise Region will be randomly selected from the municipal registries, and will be invited to participate. Healthcare workers (HCWs) All HCWs from the occupational registries of ASST Ospedale di Circolo, Varese (Lombardia) and IRCCS Neuromed, Pozzilli (Molise) will be invited to partecipate
Who may be able to join
- Signing a written consent
Who cannot join
- None
Trial locations and contacts
2 sites in 1 country.
Italy2 sites
IRCCS INM Neuromed, Department of Epidemiology and Prevention
Pozzilli, IS, 86077
ASST Settelaghi
Varese, VA
About this study
Official title: Burden of SARS-CoV-2 Infection in Populations With High or Low Risk of Infection
Introduction. Some issues remain to be elucidated about SARS-CoV-2 infection to plan prevention interventions based on scientific evidence, such as the actual prevalence of infection including subclinical and seroconverted cases, the reasons for the different spread and severity of the infection in different subjects and geographical areas as well as the impact of the COVID-19 crisis on the health of healthcare professionals and in the general population.
The aims of this project are: (i) to estimate and compare the real prevalence of the SARS-CoV-2 infection and seroconversion in two populations at high or low risk of infection,in Lombardia region and Molise region, respectively; focusing on subgroups at higher risk such as healthcare workers (HCWs); (ii) to estimate the incidence of burnout and post-traumatic stress disorder in HCWs; (iii) to identify factors associated with SARS-CoV-2 infection positivity and to follow up its mid-term effects on health.
Read more
Methods. Participants will be randomly selected from the general population of both territories and from the HCWs list of the two healthcare facilities involved. SARS-CoV-2 IgG and IgM blood levels will be measured and anamnestic data will be collected through computerized tools. Prevalence of currently or previously infected subjects and their disease status and severity will be estimated and the association with potential risk factors will be analyzed through multivariable regression analyses.
Expected results. The study will identify the burden of the infection in the general and HCWs populations. It will also identify the determinants of differences in the spread and severity of the infection, to hypothesize new preventive or therapeutic interventions. This study will provide a basis for monitoring the progress of the infection and its medium-term health consequences, Finally it will allow planning future studies, through analyses in biological samples which will be collected in dedicated biobanks.
Read the detailed description
SARS-CoV-2 infection currently affects more than two million people worldwide and has caused the death of more than 150,000 people. In Lombardia there were 64.000 confirmed positive subjects (64:10,000) and 12,000 dead, with a large number of healthcare workers (HCWs) involved. However, the number of recovered is starting to rise and, thanks to the containment measures introduced, the number of new cases per day is falling. However, the situation is quite different in other part of Italy; f.i. in Molise, a southern Italy region, there is a much lower incidence of positivity and mortality: 269 confirmed positive (9:10,000) and 16 deaths.
To plan the second phase of outbreak management, waiting for the development of a vaccine and valid therapeutic tools, preventive interventions should be revisited based on evidence from the literature and from local epidemiological data. However, although the infection is now worldwide spread, some issues are still not known.
The actual number of subjects with an active or past SARS-CoV-2 infection is not known, since the approach used was based on tests performed in severe cases and in their contacts, while few investigations have been carried out on the general population. The impact of the emergency on the health of both HCWs or general population is not yet known. Furthermore, the reasons for the different spread of the infection in the North and South of the country, as well as the different characteristics of the subjects who have or have had the infection with respect to those who have not had it are not yet fully known; moreover, among the positive ones, the characteristics associated with the development of the more serious forms or the absence of symptoms, remain to be elucidated. In fact, the studies conducted so far were large studies that collected few data or were more detailed studies focused only on few hospitalized subjects.
It is therefore necessary to conduct new studies on the general population, based on large samples randomly selected from populations at high and low spread of the infection as well as in subgroups at higher risk such as HCWs, and based on a large set of collected data. The aims of this project are: (i) to estimate the real prevalence of the SARS-CoV-2 infection and seroconversion in two populations at high and low risk of infection, in a comparative way, from the territories of ASST Sette Laghi of Varese, Lombardia region (confirmed cases 18:10,000) and a region at lower prevalence of confirmed cases such as the Molise region (confirmed cases 9:10,000 subjects), also focusing on subgroups at higher risk such as healthcare workers (HCWs); (ii) to estimate the rate of burnout and post-traumatic stress disorder in HCWs during the study period; (iii) to identify factors associated with SARS-CoV-2 infection positivity and follow up at mead-term its effect on health.
Finally, the investigators will biobank biological samples for future studies, in already available specialized facilities.
(i) Cross sectional analysis in the general population Population. Residents in the territories of ASST Sette Laghi and of Molise Region will be randomly selected from the municipal registries, up to reach 3000 recruited subjects invited to participate according to protocols used in previous study.
Data collection. All people who accept the invitation at the clinics (ASST Sette Laghi Occupational Medicine in Varese, IRCCS Neuromed in Molise) will be asked to sign the informed consent and a blood sample will be taken for testing of IgM and IgG against SARS-CoV-2 and for storage in the biobank. Laboratory analyses will be performed to assess blood cell count, CRP, glucose and insulin levels.
Serum IgM and IgG antibodies will be measured with the most suitable test available at the moment of the recruitment.
To each subject an app and a website access will be given to complete questionnaires at the time of recruitment and after 6 months.
Statistical analysis. The prevalence of positivity for IgM and IgG antibodies will be calculated and the incidence during the outbreak period will be estimated. An analysis of the differences between the two geographical areas will be performed.
(ii) Cross sectional analysis on HCWs Population. All HCWs from the occupational registries of two Clinical Centers (ASST Ospedale di Circolo and IRCCS Neuromed) will be recruited.
Data collection. The HCWs who accept the invitation will be asked to sign the informed consent and a blood sample drawn for the assay of SARS-CoV-2 IgM and IgG levels and for storage in the biobank. Laboratory analyses will be performed to assess blood cell count, CRP, glucose and insulin levels, cortisol level. To each subject an app and a website access will be provided to complete questionnaires at the time of recruitment and after 6 months. In particular, they will be asked to fill: (a) Maslach Burnout Inventory (MBI), for the detection of the burnout level; (b) peritraumatic dissociative experiences questionnaire (PTEQ) and Impact of Event Scale (IES), for the detection of symptoms attributable to PTSD; (c) a reduced scale of the General Health Questionnaire (GHQ), to assess the level of psychological distress. Clinical records for SARS-CoV-2 positive participants who were hospitalized for COVID-19 will be collected in the hospital upon informed consent signature.
Statistical analysis. The prevalence of positivity to IgM and IgG antibodies will be analyzed as described in paragraph (i). Furthermore, the prevalence and incidence of MBI and PTSD disorders and the associations between the development of conditions and anamnestic, clinical and laboratory factors will be analyzed through multivariable regression analyses.
(iii) Identification of factors associated with SARS-CoV-2 infection positivity and follow up at mead-term its effect on health.
Development of a computerized application for data collection A dedicated website will be developed to allow the administration, guided by telephone aid, of specific questionnaires. Moreover, a smartphone app will be developed to follow-up participants for phase 2 COVID-19 triage and risk factors changes. Privacy and data safety will be implemented according to Italian law and guaranteed by up to date encryption standards. Questionnaire will address participants' general information (gender, age, biometrics, socio-economic status, current and previous job), lifestyles (dietary habits, smoking status, physical activity), work or leisure travel habits, previous and current diseases, pharmacological history (drugs, vaccinations and supplements), as well as specific data about COVID-19 (if they are or have been affected by the disease or they turned out to be positive to a screening). A follow up questionnaire will evaluate evolution of COVID-19 (for affected people), together with biometrics data, nutrition, physical activity, cardiovascular and neurological disorders, cognitive ability, quality of life, modifications in socio-economic level, stress, resilience.
Statistical analysis. The differences in the different variables collected between the sample of the positive subjects and a number of controls paired by sex and age, taken from the Objective 1 population will be calculated as well as the differences between the asymptomatic/paucisymptomatic non-hospitalized positives and all the other positives separated by severity (hospitalized, COVID). The analysis will be carried out through multivariate logistic regression, considering any plausibly associated variables and checking for bias from multiple tests.
- Conditions
- SARS-CoV-2 Infection, Covid19
- Keywords
- SARS-CoV-2, Healthcare workers, General population
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| General population | A sample of 3,000 men and women, residents in the territories of ASST Sette Laghi (Lombardia) and of Molise Region will be randomly selected from the municipal registries, and will be invited to participate. | |
| Healthcare workers (HCWs) | All HCWs from the occupational registries of ASST Ospedale di Circolo Varese (Lombardia) and IRCCS Neuromed Pozzilli (Molise) will be invited to participate, up to reach 500 recruited subjects. |
What is being measured
The primary outcome is the main question the study is designed to answer.
SARS-CoV-2 infection
To estimate and compare the real prevalence of the SARS-CoV-2 infection and seroconversion in two populations at high or low risk of infection. The knowledge of the real prevalence of currently or previously infected subjects, then the actual immunization in the general population and in HCWs, will allow to estimate the real impact of the condition and to better predict the time-course of potential new outbreaks, considering the estimated impact of the herd immunity in slowing it down
Measured: From December 15 2020 to June 15 2021
Burnout and post-traumatic stress disorder in HCWs
To estimate the incidence of burnout and post-traumatic stress disorder in HCWs. To understand the impact of COVID-19 crisis on their health, also by quantifying their stress levels, and to set the priorities for intervention in this population subgroup (HCWs)
Measured: From December 15 2020 to June 15 2021
SARS-CoV-2 infection positivity factors/determinants
To identify different characteristics of the subjects who have / have had the infection or the positives who have developed more serious forms will allow better understanding of the transmission pathways or the mechanism underlying the pathogenesis of the viral infection and of its manifestations, facilitating the development of new preventive or therapeutic interventions
Measured: From December 15 2020 to December 15 2021
Secondary outcomes (2)
Population cohort of immunized subjects
It is not yet known whether the immunization acquired after the infection is effective in preventing the development of the infection following a subsequent contact with the virus. This would allow to better plan the prevention interventions on the population and also to give suggestions for the research of the specific vaccine
Measured: From December 15 2020 to June 15 2022
Biobank biospecimen collection
The biobank set up will be useful for future studies on biomarkers, which can therefore be analyzed once new hypotheses and resources are available.
Measured: From December 15 2020 to June 15 2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2020
- Study start15 Jan 2020
- Primary completion15 Sep 2022
- Study completion31 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SARS-CoV-2 InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 4,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Neuromed IRCCS
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Licia Iacoviello, Neuromed IRCCS
- Investigators
- Licia Iacoviello, MD, PhD, Principal investigator, IRCCS Neuromed
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04636203
- Sponsor's protocol ID
- DEP_032020
- Status last verified
- Nov 2023
- First submitted
- 17 Nov 2020
- Last updated
- 14 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Burden of SARS-CoV-2 Infection in Populations With High or Low Risk of Infection
- ClinicalTrials.gov ID
- NCT04636203
- Acronym / sponsor ID
- DEP_032020
- Conditions
- SARS-CoV-2 Infection, Covid19
- Keywords
- SARS-CoV-2, Healthcare workers, General population
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 4,000 participants (actual)
- Lead sponsor
- Neuromed IRCCSUniversity, hospital or other
- Study start
- 15 Jan 2020 (actual)
- Primary completion
- 15 Sep 2022 (actual)
- Study completion
- 31 Dec 2022 (actual)
- First posted
- 19 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction. Some issues remain to be elucidated about SARS-CoV-2 infection to plan prevention interventions based on scientific evidence, such as the actual prevalence of infection including subclinical and seroconverted cases, the reasons for the different spread and severity of the infection in different subjects and geographical areas as well as the impact of the COVID-19 crisis on the health of healthcare professionals and in the general population.
The aims of this project are: (i) to estimate and compare the real prevalence of the SARS-CoV-2 infection and seroconversion in two populations at high or low risk of infection,in Lombardia region and Molise region, respectively; focusing on subgroups at higher risk such as healthcare workers (HCWs); (ii) to estimate the incidence of burnout and post-traumatic stress disorder in HCWs; (iii) to identify factors associated with SARS-CoV-2 infection positivity and to follow up its mid-term effects on health.
Methods. Participants will be randomly selected from the general population of both territories and from the HCWs list of the two healthcare facilities involved. SARS-CoV-2 IgG and IgM blood levels will be measured and anamnestic data will be collected through computerized tools. Prevalence of currently or previously infected subjects and their disease status and severity will be estimated and the association with potential risk factors will be analyzed through multivariable regression analyses.
Expected results. The study will identify the burden of the infection in the general and HCWs populations. It will also identify the determinants of differences in the spread and severity of the infection, to hypothesize new preventive or therapeutic interventions. This study will provide a basis for monitoring the progress of the infection and its medium-term health consequences, Finally it will allow planning future studies, through analyses in biological samples which will be collected in dedicated biobanks.
Detailed description
SARS-CoV-2 infection currently affects more than two million people worldwide and has caused the death of more than 150,000 people. In Lombardia there were 64.000 confirmed positive subjects (64:10,000) and 12,000 dead, with a large number of healthcare workers (HCWs) involved. However, the number of recovered is starting to rise and, thanks to the containment measures introduced, the number of new cases per day is falling. However, the situation is quite different in other part of Italy; f.i. in Molise, a southern Italy region, there is a much lower incidence of positivity and mortality: 269 confirmed positive (9:10,000) and 16 deaths.
To plan the second phase of outbreak management, waiting for the development of a vaccine and valid therapeutic tools, preventive interventions should be revisited based on evidence from the literature and from local epidemiological data. However, although the infection is now worldwide spread, some issues are still not known.
The actual number of subjects with an active or past SARS-CoV-2 infection is not known, since the approach used was based on tests performed in severe cases and in their contacts, while few investigations have been carried out on the general population. The impact of the emergency on the health of both HCWs or general population is not yet known. Furthermore, the reasons for the different spread of the infection in the North and South of the country, as well as the different characteristics of the subjects who have or have had the infection with respect to those who have not had it are not yet fully known; moreover, among the positive ones, the characteristics associated with the development of the more serious forms or the absence of symptoms, remain to be elucidated. In fact, the studies conducted so far were large studies that collected few data or were more detailed studies focused only on few hospitalized subjects.
It is therefore necessary to conduct new studies on the general population, based on large samples randomly selected from populations at high and low spread of the infection as well as in subgroups at higher risk such as HCWs, and based on a large set of collected data. The aims of this project are: (i) to estimate the real prevalence of the SARS-CoV-2 infection and seroconversion in two populations at high and low risk of infection, in a comparative way, from the territories of ASST Sette Laghi of Varese, Lombardia region (confirmed cases 18:10,000) and a region at lower prevalence of confirmed cases such as the Molise region (confirmed cases 9:10,000 subjects), also focusing on subgroups at higher risk such as healthcare workers (HCWs); (ii) to estimate the rate of burnout and post-traumatic stress disorder in HCWs during the study period; (iii) to identify factors associated with SARS-CoV-2 infection positivity and follow up at mead-term its effect on health.
Finally, the investigators will biobank biological samples for future studies, in already available specialized facilities.
(i) Cross sectional analysis in the general population Population. Residents in the territories of ASST Sette Laghi and of Molise Region will be randomly selected from the municipal registries, up to reach 3000 recruited subjects invited to participate according to protocols used in previous study.
Data collection. All people who accept the invitation at the clinics (ASST Sette Laghi Occupational Medicine in Varese, IRCCS Neuromed in Molise) will be asked to sign the informed consent and a blood sample will be taken for testing of IgM and IgG against SARS-CoV-2 and for storage in the biobank. Laboratory analyses will be performed to assess blood cell count, CRP, glucose and insulin levels.
Serum IgM and IgG antibodies will be measured with the most suitable test available at the moment of the recruitment.
To each subject an app and a website access will be given to complete questionnaires at the time of recruitment and after 6 months.
Statistical analysis. The prevalence of positivity for IgM and IgG antibodies will be calculated and the incidence during the outbreak period will be estimated. An analysis of the differences between the two geographical areas will be performed.
(ii) Cross sectional analysis on HCWs Population. All HCWs from the occupational registries of two Clinical Centers (ASST Ospedale di Circolo and IRCCS Neuromed) will be recruited.
Data collection. The HCWs who accept the invitation will be asked to sign the informed consent and a blood sample drawn for the assay of SARS-CoV-2 IgM and IgG levels and for storage in the biobank. Laboratory analyses will be performed to assess blood cell count, CRP, glucose and insulin levels, cortisol level. To each subject an app and a website access will be provided to complete questionnaires at the time of recruitment and after 6 months. In particular, they will be asked to fill: (a) Maslach Burnout Inventory (MBI), for the detection of the burnout level; (b) peritraumatic dissociative experiences questionnaire (PTEQ) and Impact of Event Scale (IES), for the detection of symptoms attributable to PTSD; (c) a reduced scale of the General Health Questionnaire (GHQ), to assess the level of psychological distress. Clinical records for SARS-CoV-2 positive participants who were hospitalized for COVID-19 will be collected in the hospital upon informed consent signature.
Statistical analysis. The prevalence of positivity to IgM and IgG antibodies will be analyzed as described in paragraph (i). Furthermore, the prevalence and incidence of MBI and PTSD disorders and the associations between the development of conditions and anamnestic, clinical and laboratory factors will be analyzed through multivariable regression analyses.
(iii) Identification of factors associated with SARS-CoV-2 infection positivity and follow up at mead-term its effect on health.
Development of a computerized application for data collection A dedicated website will be developed to allow the administration, guided by telephone aid, of specific questionnaires. Moreover, a smartphone app will be developed to follow-up participants for phase 2 COVID-19 triage and risk factors changes. Privacy and data safety will be implemented according to Italian law and guaranteed by up to date encryption standards. Questionnaire will address participants' general information (gender, age, biometrics, socio-economic status, current and previous job), lifestyles (dietary habits, smoking status, physical activity), work or leisure travel habits, previous and current diseases, pharmacological history (drugs, vaccinations and supplements), as well as specific data about COVID-19 (if they are or have been affected by the disease or they turned out to be positive to a screening). A follow up questionnaire will evaluate evolution of COVID-19 (for affected people), together with biometrics data, nutrition, physical activity, cardiovascular and neurological disorders, cognitive ability, quality of life, modifications in socio-economic level, stress, resilience.
Statistical analysis. The differences in the different variables collected between the sample of the positive subjects and a number of controls paired by sex and age, taken from the Objective 1 population will be calculated as well as the differences between the asymptomatic/paucisymptomatic non-hospitalized positives and all the other positives separated by severity (hospitalized, COVID). The analysis will be carried out through multivariate logistic regression, considering any plausibly associated variables and checking for bias from multiple tests.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| General population | – | –A sample of 3,000 men and women, residents in the territories of ASST Sette Laghi (Lombardia) and of Molise Region will be randomly selected from the municipal registries, and will be invited to participate. |
| Healthcare workers (HCWs) | – | –All HCWs from the occupational registries of ASST Ospedale di Circolo Varese (Lombardia) and IRCCS Neuromed Pozzilli (Molise) will be invited to participate, up to reach 500 recruited subjects. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- General population Residents in the territories of ASST Sette Laghi (Lombardia) and of Molise Region will be randomly selected from the municipal registries, and will be invited to participate. Healthcare workers (HCWs) All HCWs from the occupational registries of ASST Ospedale di Circolo, Varese (Lombardia) and IRCCS Neuromed, Pozzilli (Molise) will be invited to partecipate
Key inclusion criteria (1 listed)
- Signing a written consent
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
SARS-CoV-2 infection
Time frame: From December 15 2020 to June 15 2021
To estimate and compare the real prevalence of the SARS-CoV-2 infection and seroconversion in two populations at high or low risk of infection. The knowledge of the real prevalence of currently or previously infected subjects, then the actual immunization in the general population and in HCWs, will allow to estimate the real impact of the condition and to better predict the time-course of potential new outbreaks, considering the estimated impact of the herd immunity in slowing it down
Burnout and post-traumatic stress disorder in HCWs
Time frame: From December 15 2020 to June 15 2021
To estimate the incidence of burnout and post-traumatic stress disorder in HCWs. To understand the impact of COVID-19 crisis on their health, also by quantifying their stress levels, and to set the priorities for intervention in this population subgroup (HCWs)
SARS-CoV-2 infection positivity factors/determinants
Time frame: From December 15 2020 to December 15 2021
To identify different characteristics of the subjects who have / have had the infection or the positives who have developed more serious forms will allow better understanding of the transmission pathways or the mechanism underlying the pathogenesis of the viral infection and of its manifestations, facilitating the development of new preventive or therapeutic interventions
2 secondary outcomes
Population cohort of immunized subjects
Time frame: From December 15 2020 to June 15 2022
Biobank biospecimen collection
Time frame: From December 15 2020 to June 15 2022
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2023.
- Individual participant dataSharing planned: No
Related trials for SARS-CoV-2 Infection
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Licia Iacoviello, MD, PhD principal investigator
IRCCS Neuromed
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of SARS-CoV-2 Infection and Covid19, run by Neuromed IRCCS at 2 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SARS-CoV-2 infection (time frame: From December 15 2020 to June 15 2021). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2023.